Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Recruiting · NCT07184619 · Registry updated 2026-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Treatment-Resistant, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-10 | NCT07184619 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Newron Pharmaceuticals SPA | 1 |
19 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.